To read the full story, subscribe or sign in.

Enrollment target reached in phase IIIb study of Onconase

March 2, 2006

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for May 11, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

BioWorld

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...